<p>印第安纳波利斯 --（商业资讯）--Elevance Health, Inc.（纽约证券交易所代码：ELV）今天宣布了一系列管理变动，旨在简化决策过程并加强 Carelon 和健康福利的执行力。</p>
<p>作为这些变动的一部分，执行副总裁兼首席财务官 Mark Kaye 将扩大其职责，负责监督 Carelon，该公司提供包括药房服务、行为健康、基于价值的护理和护理交付能力在内的医疗服务运营。Carelon 在推动公司降低护理成本的战略中发挥着关键作用。Carelon 的运营优先事项和客户承诺保持不变。</p>
<p>执行副总裁兼首席健康福利官 Felicia Norwood 将负责公司的综合健康福利组织，将公司的主要健康福利业务和核心运营职能整合到一个可问责的结构下。这一整合增强了商业和政府健康福利之间的协调，并支持产品、运营和增长优先事项之间更一致的运营节奏。</p>
<p>Peter D. Haytaian 已宣布，他将于 2026 年 5 月 4 日起从执行副总裁兼 Carelon 总裁的职位上过渡，以便投入更多时间于家庭事务。Haytaian 将担任公司的特别顾问，直至 2026 年 12 月 31 日，以支持有序的领导过渡，并确保 Carelon 的运营及客户和合作伙伴关系的连续性。</p>
<p>“在过去的几年里，我们不断演变我们的运营方式，以满足医疗保健的变化需求，并为我们的客户、会员和合作伙伴提供服务，” Elevance Health 的总裁兼首席执行官 Gail Boudreaux 表示。“这些管理变动支持有序的执行，并帮助我们在继续扩展的过程中以更清晰和协调的方式行动。我还要感谢 Pete 的领导和他对支持顺利过渡的承诺。”</p>
<p>“我期待领导 Carelon 团队，基于我们坚实的基础，为客户和合作伙伴提供服务，并以支持可持续增长和长期价值的纪律性执行，” Kaye 说道。</p>
<p>Norwood 补充道：“将健康福利整合到一个可问责的结构下，增强了协调和执行力，使我们能够继续为会员和客户提供服务。”</p>
<p><strong>关于 Elevance Health</strong></p>
<p>Elevance Health 是一个终身值得信赖的健康合作伙伴，其宗旨是改善人类健康。该公司支持消费者、家庭和社区在整个医疗保健旅程中，帮助他们连接到所需的护理、支持和资源，以过上更好的生活。Elevance Health 的公司通过多样化的行业领先医疗、药房、行为、临床、家庭健康和复杂护理解决方案，服务约 1.04 亿消费者。欲了解更多信息，请访问 www.elevancehealth.com 或在 X 上关注我们 @ElevanceHealth，在 LinkedIn 上关注 Elevance Health。</p>
<p><strong>前瞻性声明</strong></p>
<p>本文件包含 1995 年《私人证券诉讼改革法案》所定义的某些前瞻性陈述。前瞻性陈述反映了我们对未来事件和财务表现的看法，通常不是历史事实。诸如 “期望”、“感觉”、“相信”、“将”、“可能”、“应该”、“预期”、“打算”、“估计”、“项目”、“预测”、“计划”、“潜在”、“预测” 等词语旨在识别前瞻性陈述。这些陈述包括但不限于：财务预测和估计及其基本假设；关于未来运营、产品和服务的计划、目标和期望的陈述；以及关于未来表现的陈述。这些陈述受到某些风险和不确定性的影响，其中许多是难以预测的，通常超出我们的控制范围，可能导致实际结果与前瞻性陈述中表达、暗示或预测的结果有重大差异。请注意，不要对这些仅在本日期时有效的前瞻性陈述过于依赖。我们还敦促您仔细审查和考虑我们不时向美国证券交易委员会提交的报告中讨论的各种风险和其他披露，这些报告试图告知相关方影响我们业务的因素。除法律要求外，我们不会更新或修订任何前瞻性陈述，以反映本日期后发生的事件或情况。这些风险和不确定性包括但不限于：医疗成本和利用率的趋势；注册人数减少；我们确保和实施足够保费率的能力；大规模医疗紧急情况的影响，例如公共卫生流行病和其他灾难；新法律或现有联邦、州和国际法律或法规的变化及其影响，包括影响医疗、保险、药房服务和其他多元化产品和服务的法律法规，或其执行或适用；网络攻击或其他隐私或数据安全事件的影响，或我们未能遵守任何隐私、数据或安全法律法规，包括与此相关的任何调查、索赔或诉讼；未能有效维护和现代化我们的信息系统；我们的信息系统或技术（包括人工智能）未能按预期运行；未能有效维护我们数据的可用性和完整性；经济和市场条件的变化，以及可能对我们的流动性和投资组合产生负面影响的法规；竞争压力以及我们适应行业变化和开发、实施战略增长机会的能力；关于医疗保险和医疗补助计划的风险和不确定性，包括与复杂法规不合规相关的风险；我们在医疗保险和医疗补助服务中心的星级评分和其他质量评分的维持和改善能力，以及与参与其中所获得收入相关的资金风险；我们医疗产品组合的负面变化；与诉讼、政府调查、审计或审查相关的成本和其他责任；我们与提供者以具有成本效益和竞争力的条款签订合同的能力；提供医疗、药房和其他多元化产品和服务的风险，包括医疗事故或专业责任索赔，以及任何一方未能遵守我们与 CaremarkPCS Health, L.L.C.之间的药房服务协议；与健康福利行业或我们本身相关的任何负面宣传或情绪的影响；与并购、合资企业和战略联盟相关的风险；如果未来结果未能充分支持商誉和其他无形资产，可能导致我们无形资产价值的减值；从我们的子公司支付股息的可能限制以及对最低资本水平的要求增加；由于现金流和收益的充足性及其他考虑，我们回购普通股和支付普通股股息的能力；我们大量未偿债务可能产生的潜在负面影响，以及利率上升或市场波动可能影响我们融资的获取或进一步增加融资成本的风险；我们财务实力评级的下调；可能对我们与蓝十字蓝盾协会的许可证产生负面影响的事件；吸引和留住员工的激烈竞争；与我们国际业务相关的风险；以及我们治理文件中的各种法律和条款，可能阻止或阻碍收购和商业合并。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260226217741/en/</p>
<p>Elevance Health 联系人：</p>
<p><strong>投资者关系：</strong></p>
<p>Nathan Rich</p>
<p>Investor.Relations@elevancehealth.com</p>
<p><strong>媒体联系人：</strong></p>
<p>Leslie Porras</p>
<p>Leslie.Porras@elevancehealth.com</p>
<p>来源：Elevance Health, Inc.</p>

美国医疗保健供应商 ETF - iShares

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

<p>Elevance Health, Inc. 宣布管理层变动，以增强其 Carelon 和健康福利部门的决策和执行能力。首席财务官 Mark Kaye 现在将负责 Carelon，而 Felicia Norwood 将领导整合后的健康福利组织。Peter D. Haytaian 将从 Carelon 总裁的职位转任特别顾问。这些变动旨在改善协调，支持公司的可持续增长</p>

<p>INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits.</p>
<div class="lb-trans"><p>印第安纳波利斯 --（商业资讯）--Elevance Health, Inc.（纽约证券交易所代码：ELV）今天宣布了一系列管理变动，旨在简化决策过程并加强 Carelon 和健康福利的执行力。</p>
</div><p>As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company’s healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company’s strategy to lower the cost of care. Carelon’s operating priorities and client commitments remain unchanged.</p>
<div class="lb-trans"><p>作为这些变动的一部分，执行副总裁兼首席财务官 Mark Kaye 将扩大其职责，负责监督 Carelon，该公司提供包括药房服务、行为健康、基于价值的护理和护理交付能力在内的医疗服务运营。Carelon 在推动公司降低护理成本的战略中发挥着关键作用。Carelon 的运营优先事项和客户承诺保持不变。</p>
</div><p>Felicia Norwood, Executive Vice President and Chief Health Benefits Officer, will assume responsibility for the Company’s consolidated Health Benefits organization, bringing together the Company’s major Health Benefits businesses and core operating functions under a single accountable structure. This consolidation enhances coordination across Commercial and Government health benefits and supports a more consistent operating cadence across product, operations, and growth priorities.</p>
<div class="lb-trans"><p>执行副总裁兼首席健康福利官 Felicia Norwood 将负责公司的综合健康福利组织，将公司的主要健康福利业务和核心运营职能整合到一个可问责的结构下。这一整合增强了商业和政府健康福利之间的协调，并支持产品、运营和增长优先事项之间更一致的运营节奏。</p>
</div><p>Peter D. Haytaian has announced that he will transition from his role as Executive Vice President and President of Carelon effective May 4, 2026, in order to devote more time to family commitments. Haytaian will serve the Company as Special Advisor through December 31, 2026, to support an orderly leadership transition and ensure continuity across Carelon’s operations and client and partner relationships.</p>
<div class="lb-trans"><p>Peter D. Haytaian 已宣布，他将于 2026 年 5 月 4 日起从执行副总裁兼 Carelon 总裁的职位上过渡，以便投入更多时间于家庭事务。Haytaian 将担任公司的特别顾问，直至 2026 年 12 月 31 日，以支持有序的领导过渡，并确保 Carelon 的运营及客户和合作伙伴关系的连续性。</p>
</div><p>“Over the last several years, we have continued to evolve how we operate to meet the changing needs of healthcare and deliver for our customers, members, and clients,” said Gail Boudreaux, President and Chief Executive Officer of Elevance Health. “These management changes support disciplined execution and help us move with greater clarity and coordination as we continue to scale. I also want to thank Pete for his leadership and his commitment to supporting a smooth transition.”</p>
<div class="lb-trans"><p>“在过去的几年里，我们不断演变我们的运营方式，以满足医疗保健的变化需求，并为我们的客户、会员和合作伙伴提供服务，” Elevance Health 的总裁兼首席执行官 Gail Boudreaux 表示。“这些管理变动支持有序的执行，并帮助我们在继续扩展的过程中以更清晰和协调的方式行动。我还要感谢 Pete 的领导和他对支持顺利过渡的承诺。”</p>
</div><p>“I look forward to leading the Carelon team as we build on our strong foundation, deliver for clients and partners, and execute with discipline that supports sustainable growth and long-term value,” said Kaye.</p>
<div class="lb-trans"><p>“我期待领导 Carelon 团队，基于我们坚实的基础，为客户和合作伙伴提供服务，并以支持可持续增长和长期价值的纪律性执行，” Kaye 说道。</p>
</div><p>Norwood added, “Bringing Health Benefits together under a single accountable structure strengthens coordination and execution as we continue delivering for members and customers.”</p>
<div class="lb-trans"><p>Norwood 补充道：“将健康福利整合到一个可问责的结构下，增强了协调和执行力，使我们能够继续为会员和客户提供服务。”</p>
</div><p><strong>About Elevance Health</strong></p>
<div class="lb-trans"><p><strong>关于 Elevance Health</strong></p>
</div><p>Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 104 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.</p>
<div class="lb-trans"><p>Elevance Health 是一个终身值得信赖的健康合作伙伴，其宗旨是改善人类健康。该公司支持消费者、家庭和社区在整个医疗保健旅程中，帮助他们连接到所需的护理、支持和资源，以过上更好的生活。Elevance Health 的公司通过多样化的行业领先医疗、药房、行为、临床、家庭健康和复杂护理解决方案，服务约 1.04 亿消费者。欲了解更多信息，请访问 www.elevancehealth.com 或在 X 上关注我们 @ElevanceHealth，在 LinkedIn 上关注 Elevance Health。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p><em>This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems; failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.</em></p>
<div class="lb-trans"><p>本文件包含 1995 年《私人证券诉讼改革法案》所定义的某些前瞻性陈述。前瞻性陈述反映了我们对未来事件和财务表现的看法，通常不是历史事实。诸如 “期望”、“感觉”、“相信”、“将”、“可能”、“应该”、“预期”、“打算”、“估计”、“项目”、“预测”、“计划”、“潜在”、“预测” 等词语旨在识别前瞻性陈述。这些陈述包括但不限于：财务预测和估计及其基本假设；关于未来运营、产品和服务的计划、目标和期望的陈述；以及关于未来表现的陈述。这些陈述受到某些风险和不确定性的影响，其中许多是难以预测的，通常超出我们的控制范围，可能导致实际结果与前瞻性陈述中表达、暗示或预测的结果有重大差异。请注意，不要对这些仅在本日期时有效的前瞻性陈述过于依赖。我们还敦促您仔细审查和考虑我们不时向美国证券交易委员会提交的报告中讨论的各种风险和其他披露，这些报告试图告知相关方影响我们业务的因素。除法律要求外，我们不会更新或修订任何前瞻性陈述，以反映本日期后发生的事件或情况。这些风险和不确定性包括但不限于：医疗成本和利用率的趋势；注册人数减少；我们确保和实施足够保费率的能力；大规模医疗紧急情况的影响，例如公共卫生流行病和其他灾难；新法律或现有联邦、州和国际法律或法规的变化及其影响，包括影响医疗、保险、药房服务和其他多元化产品和服务的法律法规，或其执行或适用；网络攻击或其他隐私或数据安全事件的影响，或我们未能遵守任何隐私、数据或安全法律法规，包括与此相关的任何调查、索赔或诉讼；未能有效维护和现代化我们的信息系统；我们的信息系统或技术（包括人工智能）未能按预期运行；未能有效维护我们数据的可用性和完整性；经济和市场条件的变化，以及可能对我们的流动性和投资组合产生负面影响的法规；竞争压力以及我们适应行业变化和开发、实施战略增长机会的能力；关于医疗保险和医疗补助计划的风险和不确定性，包括与复杂法规不合规相关的风险；我们在医疗保险和医疗补助服务中心的星级评分和其他质量评分的维持和改善能力，以及与参与其中所获得收入相关的资金风险；我们医疗产品组合的负面变化；与诉讼、政府调查、审计或审查相关的成本和其他责任；我们与提供者以具有成本效益和竞争力的条款签订合同的能力；提供医疗、药房和其他多元化产品和服务的风险，包括医疗事故或专业责任索赔，以及任何一方未能遵守我们与 CaremarkPCS Health, L.L.C.之间的药房服务协议；与健康福利行业或我们本身相关的任何负面宣传或情绪的影响；与并购、合资企业和战略联盟相关的风险；如果未来结果未能充分支持商誉和其他无形资产，可能导致我们无形资产价值的减值；从我们的子公司支付股息的可能限制以及对最低资本水平的要求增加；由于现金流和收益的充足性及其他考虑，我们回购普通股和支付普通股股息的能力；我们大量未偿债务可能产生的潜在负面影响，以及利率上升或市场波动可能影响我们融资的获取或进一步增加融资成本的风险；我们财务实力评级的下调；可能对我们与蓝十字蓝盾协会的许可证产生负面影响的事件；吸引和留住员工的激烈竞争；与我们国际业务相关的风险；以及我们治理文件中的各种法律和条款，可能阻止或阻碍收购和商业合并。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMjYyMTc3NDFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260226217741r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260226217741/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260226217741/en/</p>
</div><p>Elevance Health Contacts:</p>
<div class="lb-trans"><p>Elevance Health 联系人：</p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投资者关系：</strong></p>
</div><p>Nathan Rich</p>
<div class="lb-trans"><p>Nathan Rich</p>
</div><p>Investor.Relations@elevancehealth.com</p>
<div class="lb-trans"><p>Investor.Relations@elevancehealth.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系人：</strong></p>
</div><p>Leslie Porras</p>
<div class="lb-trans"><p>Leslie Porras</p>
</div><p>Leslie.Porras@elevancehealth.com</p>
<div class="lb-trans"><p>Leslie.Porras@elevancehealth.com</p>
</div><p>Source: Elevance Health, Inc.</p>
<div class="lb-trans"><p>来源：Elevance Health, Inc.</p>
</div>

Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization | ELV Stock News

Elevance Health 宣布管理层变动：首席财务官 Mark Kaye 将扩大职责范围，涵盖 Carelon，Felicia Norwood 将负责领导合并后的健康福利组织 | ELV 股票新闻